# Personalized mRNA melanoma vaccine cuts recurrence risk in late-stage trial

https://mins.news/en/item/113238

- NBC News, 2026-10-23 18:42 UTC
- Health
- Original: https://www.nbcnews.com/health/cancer/personalized-mrna-vaccine-melanoma-cut-risk-cancers-return-late-stage-rcna605208

> Trial data show a 42% lower combined chance of melanoma returning or patients dying among recipients of Moderna and Merck’s tailored mRNA shot than with usual care.

## Related coverage

- [Oncologists applaud melanoma data as Moderna shares tumble](https://mins.news/en/item/113297) — Bloomberg News, 2026-10-23
- [Doctors call Moderna and Merck cancer vaccine data a major advance despite Wall Street reaction](https://mins.news/en/item/113063) — CNBC, 2026-10-23
- [Novel mRNA cancer vaccine cuts melanoma recurrence risk in major study](https://mins.news/en/item/112975) — CBC News, 2026-10-23
- [Cancer vaccine lowers risk of melanoma tumors returning](https://mins.news/en/video/111892) — The Associated Press, 2026-10-22